Sign up Australia
Proactive Investors - Run By Investors For Investors

Anteo Diagnostics surges on lithium-ion leverage

U.S. battery consulting company is engaged for the six month project.
Laboratory
The nano-coating product is being tested for possible commercialisation

Anteo Diagnostics Ltd (ASX:ADO) surged 64% to $0.023 late morning on news of a development project for its AnteoCoat nano-coating technology for lithium-ion batteries.

U.S.-based battery consulting company Polaris Battery Labs LLC has been engaged for the six month project.

The data generated is expected to play an important part in Anteo’s commercialisation strategy for the technology.

Polaris will examine the impact of various concentrations of AnteoCoat on a variety of ratios of silicon incorporated into an anode.

Performance of AnteoCoat to be examined

The project will also examine the performance of AnteoCoat on half-cell and full-cell battery prototypes.

The final aspect will be the modelling of these results such that the overall impact of AnteoCoat on lithium-ion anode battery performance can be fully characterised and documented.

It is expected that the results will provide a basis for understanding the impact of AnteoCoat on other components of lithium ion batteries such as the battery cathode.

Data package to be generated

A comprehensive data package is expected to be generated by June 2018 providing Anteo with sufficient material to continue discussions with battery manufacturers.

Further studies are likely to be required on full-cell batteries to provide an understanding of how the product can be commercialised into existing battery technologies and production processes.

Strong buying of shares

The news sparked strong buying with more than 60 million shares traded during the morning.

Anteo Group is a nano-chemistry technology and medical supply group, developing, commercialising, manufacturing and distributing products.

These products are targeted at the life sciences, IVD, point of care, medical devices and energy markets.

View full ADO profile View Profile

Anteo Diagnostics Ltd Timeline

Article
September 09 2016

Related Articles

cancer cells in blood
Tue
It’s been a tricky year for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
couple in bed
March 14 2018
MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate, or carry significant side-effects
test tubes
January 23 2018
Under former chief executive Peter George and his successor Shaun Chilton, it has been transformed via a series of well-judged, quickly integrated and, crucially, cash generative acquisitions

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use